BrightGene Bio-Medical Technology Co., Ltd.

SHSE:688166 Rapport sur les actions

Capitalisation boursière : CN¥11.3b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

BrightGene Bio-Medical Technology Croissance future

Future contrôle des critères 2/6

BrightGene Bio-Medical Technology is forecast to grow earnings and revenue by 16.8% and 15% per annum respectively. EPS is expected to grow by 16.8% per annum. Return on equity is forecast to be 9.6% in 3 years.

Informations clés

16.8%

Taux de croissance des bénéfices

16.8%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices18.8%
Taux de croissance des recettes15.0%
Rendement futur des capitaux propres9.6%
Couverture par les analystes

Low

Dernière mise à jour02 Aug 2024

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Some BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) Shareholders Look For Exit As Shares Take 29% Pounding

Aug 01
Some BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) Shareholders Look For Exit As Shares Take 29% Pounding

BrightGene Bio-Medical Technology Co., Ltd.'s (SHSE:688166) 47% Share Price Surge Not Quite Adding Up

May 21
BrightGene Bio-Medical Technology Co., Ltd.'s (SHSE:688166) 47% Share Price Surge Not Quite Adding Up

BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Mar 01
BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Prévisions de croissance des bénéfices et des revenus

SHSE:688166 - Estimations futures des analystes et données financières antérieures (CNY Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20261,8263093034672
12/31/20251,5382591463902
12/31/20241,333219363482
3/31/20241,215196-48318N/A
12/31/20231,180202-209195N/A
9/30/20231,160234-185204N/A
6/30/20231,104237-161319N/A
3/31/20231,074250-176366N/A
12/31/20221,017240-415311N/A
9/30/20221,076265-533299N/A
6/30/20221,074249-665207N/A
3/31/20221,112256-821143N/A
12/31/20211,052244-734176N/A
9/30/20211,023225-765149N/A
6/30/2021961203-656109N/A
3/31/2021844184-439164N/A
12/31/2020785170-200155N/A
9/30/2020700169-50144N/A
6/30/2020596143-32117N/A
3/31/2020544129-3870N/A
12/31/2019503111-2861N/A
9/30/201946696-2041N/A
6/30/201944583-10052N/A
3/31/201941074-9143N/A
12/31/201840873-4864N/A
12/31/201731746N/A36N/A
12/31/201620117N/A30N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: 688166's forecast earnings growth (16.8% per year) is above the savings rate (2.9%).

Bénéfices vs marché: 688166's earnings (16.8% per year) are forecast to grow slower than the CN market (21.9% per year).

Croissance élevée des bénéfices: 688166's earnings are forecast to grow, but not significantly.

Chiffre d'affaires vs marché: 688166's revenue (15% per year) is forecast to grow faster than the CN market (13.4% per year).

Croissance élevée des revenus: 688166's revenue (15% per year) is forecast to grow slower than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: 688166's Return on Equity is forecast to be low in 3 years time (9.6%).

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y